Preclinical studies of a kidney safe iodinated contrast agent.
Rowe ES, Rowe VD, Biswas S, Mosher,G.,Insisienmay, L, Ozias, MK, Gralinski, MR, Hunter, J.,Barnett JR.
J Neuroimaging 2016;26:511-8.
ABSTRACT
Background and Purpose
Contrast Induced Acute Kidney Injury (CI-AKI) is a serious complication of the use of iodinated contrast agents. This problem is particularly acute in interventional neurology and interventional cardiology, probably due to the intra-arterial route of injection, high contrast volumes, and pre-existing risk factors of these patients. In an attempt to develop a contrast agent that is less damaging to the kidneys, we have studied the effects of adding a small amount of the substituted cyclodextrin, sulfobutyl-ether-β-cyclodextrin (SBECD), to iohexol in rodent models of renal toxicity.
Conclusion:
We have shown that the addition of a small amount of SBECD (one molecule of SBECD per forty iohexol molecules) significantly protects rodent kidneys from CI-AKI. Further development of this new formulation of iodinated contrast is warranted.
A Nephroprotective Iodinated Contrast Agent with Carioprotective Properties: A Pilot Study
Rowe ES, Rowe VD, Hunter, J. Gralinski, MR, Neves, LA.,
J Neuroimaging 2021;31:706-713.
ABSTRACT
Background and Purpose:
Evaluation and treatment of acute ischemic syndromes, in the heart and the brain, require vessel visualization by iodinated X-Ray contrast agents. However, these contrast agents can induce injury, in both the kidneys and the target organs themselves. Sulfobutylether beta cyclodextrin (SBECD) added to iohexol (SBECD-iohexol)(CE-iohexol, Ligand Pharmaceuticals) is currently in clinical trials in cardiovascular procedures, to determine its relative renal safety in high risk patients. Preclinical studies showed that SBECD-iohexol reduced contrast-induced acute kidney injury (CI-AKI) in rodent models by blocking apoptosis. The current study was undertaken to determine whether SBECD-iohexol is also cardioprotective, in the male rat ischemia-reperfusion model, compared to iohexol alone.
Conclusion:
The results of this study suggest that SBECD-iohexol is superior to iohexol alone, for both the preservation of cardiomyocyte integrity, and for preservation of myocardial function in myocardial ischemia.